Samsung BioLogics signs a contract with STCube

Samsung BioLogics said Tuesday that it has signed a contract development service agreement for STCube’s anticancer drug candidate.

Under the agreement, Samsung BioLogics will lead cell line development, process development and the manufacturing of the STT-033 antibody for non-clinical and clinical studies. STCube said that the STT-033 antibody, developed from STCube’s research center in Maryland, was found to have better anticancer effects than conventional PD-1/PD-L1 therapies and has been a subject of a material transfer agreement with a multinational pharmaceutical company.

STCube is a Korean biopharmaceutical company focused on developing cancer therapies. The company plans to submit an investigational new drug application for the STT-033 antibody next year, for use as a monotherapy and combination therapy with clinical trials planned at medical institutions in the United States.

By Ko Jun-tae